Approved

Tris Pharma Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

Lead Product(s): Methylphenidate Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Quillivant XR

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: KYE Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 09, 2020

Details:

Under the terms of the agreement, KYE has received exclusive rights to commercialize Tris' FDA-approved ADHD product portfolio in Canada. Also, KYE will handle all ongoing Canadian regulatory activities for the products.

Titan Pharmaceuticals Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership

Lead Product(s): Buprenorphine

Therapeutic Area: Psychiatry/Psychology Product Name: Probuphine

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Indegene Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 24, 2020

Details:

The partnership will establish multichannel digital marketing programs throughout the United States and expand the capabilities for the engagement of health care providers ("HCPs") who are eligible to prescribe Titan's Probuphine® (buprenorphine) implant.

Tanner Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

Lead Product(s): Clozapine

Therapeutic Area: Psychiatry/Psychology Product Name: Versacloz

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Tasmanian Alkaloids Pty Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 22, 2020

Details:

Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.

Ironshore Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ironshore to Present a Dose Conversion Poster at the 2020 American Society of Clinical Psychopharmacology Virtual Scientific Poster Session

Lead Product(s): Methylphenidate Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Jornay PM

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 08, 2020

Details:

The data presented in the poster may help guide clinicians to target an appropriate dose range of JORNAY PM extended-release capsules CII, which was approved in August 2018 by the U.S. FDA for the treatment of ADHD in patients 6 years and older.

Luye Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel® and Seroquel XR®

Lead Product(s): Quetiapine Fumarate

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Alvogen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 01, 2020

Details:

Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand.

Camurus

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Lead Product(s): Buprenorphine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

The pivotal Phase 3 efficacy and safety trial demonstrated that Brixadi met the primary endpoint of non-inferiority for responder rate vs current standard of care and superiority for the secondary endpoint for the percentage of negative opioid assessments.

Luye Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CNS Business

Lead Product(s): Quetiapine Fumarate

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Moksha8

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 14, 2020

Details:

Moksha8 subsideries, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda and Moksha8 Farmacéutica, S. de R.L. de C.V have been granted the exclusive promotion rights for the two central nervous system (CNS) drugs: Seroquel® and Seroquel XR® in Brazil and Mexico.

Luye Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Cipla Medpro Gets Distribution and Marketing Rights for Seroquel

Lead Product(s): Quetiapine Fumarate

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Cipla Medpro

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 10, 2020

Details:

Luye Pharma granted the distribution and marketing rights to Cipla Medpro in South Africa and neighbouring countries on the basis of its robust business network and resources in local markets.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Tris Pharma Inc

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

Titan Pharmaceuticals Inc

Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership

Tanner Pharma

Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

Ironshore Pharmaceuticals

Ironshore to Present a Dose Conversion Poster at the 2020 American Society of Clinical Psychopharmacology Virtual Scientific Poster Session

Luye Pharma

Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel® and Seroquel XR®

Camurus

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Luye Pharma

Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CNS Business

Luye Pharma

Cipla Medpro Gets Distribution and Marketing Rights for Seroquel